Table 1.

Published cases of patients with metastatic NRG1 fusion‐driven solid tumors who were treated with afatinib

Age, gender, ethnicity, a authors’ country of origin	Tumor type	NRG1 fusion partner	NRG1 fusion detection method	Best response, physician assessed (duration in months)	Reference
Cases of lung cancer
42 yr, male, white, U.S.	Nonmucinous ADC	SLC3A2	RNA sequencing	PR (12)	[15]
62 yr, male, white, U.S.	Mucinous ADC	CD74	RNA sequencing	Durable response (10)	[15]
43 yr, female, Canada	Nonmucinous ADC	SDC4	WGTA	PR (12)	[16]
62 yr, female, Asian, Canada	Invasive mucinous ADC	CD74	NGS solid fusion assay	PR (6.5)	[17]
86 yr, male, U.S.	Invasive mucinous ADC	CD74	MSK‐IMPACT	PD (19)	[12]
81 yr, male, U.S.	Invasive mucinous ADC	CD74	MSK‐Solid Fusion Assay, Archer FusionPlex	SD (1.4)	[12]
56 yr, female, U.S.	Invasive mucinous ADC	SDC4	MSK‐Solid Fusion Assay	PD (at 1.2)	[12]
51 yr, male, U.S.	Invasive mucinous ADC	CD74	MSK‐IMPACT	PD (at 1.8)	[12]
Cases of gastrointestinal cancer
59 yr, male, Canada	PDAC	ATP1B1	WGTA	PR (5.5)	[18, 20]
54 yr, male, Canada	PDAC	APP	WGTA	PR (9)	[18, 20]
30 yr, female, Germany	PDAC	ATP1B1	WGTA	PR (3)	[11]
38 yr, female, Canada	Cholangiocarcinoma	ATP1B1	WGTA and FISH	Response (8)	[16]
Cases of genitourinary cancers
NA, female, Finland	LGS ovarian cancer	CLU	RNA sequencing	Disease control (>36) b	[19]

^aIf reported.

^bTreatment included afatinib monotherapy followed by a combination of trastuzumab and pertuzumab.

Abbreviations: ADC, adenocarcinoma; FISH, fluorescence in situ hybridization; LGS, low‐grade serous; NA, not available; NRG1, neuregulin 1; NGS, next‐generation sequencing; PD, progressive disease; PDAC, pancreatic ductal adenocarcinoma; PR, partial response; SD, stable disease; WGTA, whole‐genome and transcriptome analysis.